Spectrofluorimetric method for determination of bupropion in pharmaceutical dosage forms

Ann Pharm Fr. 2019 Nov;77(6):460-467. doi: 10.1016/j.pharma.2019.08.002. Epub 2019 Sep 26.

Abstract

Objective: Bupropion is a noradrenaline and dopamine reuptake inhibitor which is used as an antidepressant drug. Few HPLC and spectrophotometric methods have been reported before for the determination of bupropion. Most of the previous methods reported for determination of bupropion in pharmaceutical dosage forms are somehow dangerous to health and environment because of using organic solvents.

Method: In the present method bupropion was determined in pharmaceutical dosage forms by spectrofluorimetry after ion-pair complex formation with eosin Y. The ion-pair complex formation was optimized for reagent amount, buffer pH and time.

Result: The developed method was linear over the range of 3-120μgmL-1 with an acceptable precision (CV<1.5%) and accuracy (Error<1%).

Conclusion: The present method is applicable for determination of bupropion in pharmaceutical dosage forms for routine quality control analysis.

Keywords: Bupropion; Complex formation; Eosin Y; Formation d’un complexe; Ion-pair; Paire d’ions; Spectrofluorimetry; Spectrofluorimétrie; Éosine Y.

Publication types

  • Validation Study

MeSH terms

  • Bupropion / administration & dosage
  • Bupropion / analysis*
  • Dosage Forms
  • Eosine Yellowish-(YS)
  • Hydrogen-Ion Concentration
  • Ions / chemistry
  • Molecular Structure
  • Spectrometry, Fluorescence / methods*
  • Spectrophotometry
  • Tablets

Substances

  • Dosage Forms
  • Ions
  • Tablets
  • Bupropion
  • Eosine Yellowish-(YS)